

**PerCP/Cy5.5 anti-human TIGIT (VSTM3)**

**Catalog # / Size:** 2463590 / 100 tests  
2463585 / 25 tests

**Clone:** A15153G

**Isotype:** Mouse IgG2a, κ


**Immunogen:** Recombinant Human TIGIT.

**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography and conjugated with PerCP/Cy5.5 under optimal conditions. The solution is free of unconjugated PerCP/Cy5.5 and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

**Concentration:** Lot-specific




Human peripheral blood leukocytes were stained with CD3 FITC and TIGIT (clone A15153G) PerCP/Cy5.5 (top) or mouse IgG2a, κ PerCP/Cy5.5 isotype control (bottom). Data shown was gated on the lymphocyte population.

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.



\* PerCP/Cy5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

**Application Notes:** This clone can suppress anti-CD3 induced T cell proliferation *in vitro*.

**Description:** T cell immunoreceptor with Ig and ITIM domains (TIGIT), also known as VSTM3 or WUCAM, is a 26 kD, type I transmembrane protein and is a member of the PVR (poliovirus receptor) family of immunoglobulin-like domain containing proteins. TIGIT is expressed on activated T cells, follicular T helper, memory, and regulatory T cells as well as on NK cells. TIGIT is a negative regulator of NK and T cell activation. Expression of TIGIT is associated with decreased functionality of CD8 T cells in chronic viral infection and tumors. TIGIT also promotes the differentiation of tolerogenic phenotype in dendritic cells with an increased secretion of IL-10 and a diminished production of IL-12.

**Antigen** 1. Stanietsky N, *et al.* 2009. *Proc. Natl. Acad. Sci.* 106:17858.

- References:**
2. Yu X, *et al.* 2009. *Nat. Immunol.* 10:48.
  3. Johnston R, *et al.* 2014. *Cancer Cell.* 26:923.